European equities traded in the US as American depositary receipts were moving sharply lower late Tuesday morning, falling 1.21% to 1,404.91 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which rose 2.6% and 2.3%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and furniture maker Natuzzi (NTZ), which were down 1.5% and 1.4%, respectively.
The decliners from continental Europe were led by telecommunications company VEON (VEON) and medical device maker EDAP TMS (EDAP), which retreated 6.9% and 3.5%, respectively. Biopharmaceutical firm Grifols (GRFS) lost 3.3% and financial services company Banco Santander (SAN) was down 2.8%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which advanced 8.5% and 3.9%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Mereo BioPharma Group (MREO), which rose 3.6% and 2.3%, respectively.
The decliners from the UK and Ireland were led by financial services companies Barclays (BCS) and Lloyds Banking Group (LYG), which fell 3% and 2.8%, respectively. Biopharmceutical company NuCana (NCNA) was down 2.6% and financial services company HSBC (HSBC) lost 2.3%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。